Argo Biopharma has raised $41 million in an extended Series A round, while Anxinmuye plans to boost its registered capital by $36.9 million. Meanwhile, Temasek-backed Temus has expanded to Hong Kong.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
